LillyPod, which occupies 30,000 square feet in a room the size of a football field, is capable of crunching massive amounts of data at high speeds and is expected to help the Lilly discover and develop drugs at a faster pace.
Read More
Officials say the pact, facilitated by the Indianapolis-based IU Launch Accelerator for Biosciences, is the largest single industry-sponsored agreement in the school’s history.
Read More
The Indianapolis-based drugmaker will work to support UNICEF’s efforts to strengthen primary health care systems to prevent, detect and manage noncommunicable diseases in children and adolescents.
The Indianapolis-based drugmaker is marking 150 years since Col. Eli Lilly founded his company on May 10, 1876.
Former Indianapolis Colts quarterback Peyton Manning emceed the event, which took place before about 500 attendees at the new Lilly Event Center in downtown Indianapolis.
The move comes as Lilly has embarked on a spree of large acquisitions, including two of its most-expensive transactions ever.
Lilly’s latest commitment at the LEAP District brings the company’s total investment there since 2022 to $18 billion.
A real estate leader and pharmaceutical executive explain the practical and surprising ways they’re using AI in their fields and what the future might look like for AI and their industries..
The Indianapolis-based drugmaker reported profit of $7.4 billion for the first quarter, up from $2.8 billion in the same period a year earlier.
The Indianapolis-based drugmaker will partner with Profluent to develop and commercialize treatments for diseases with severe unmet needs.
The acquisition is the latest in a series of recent deals that Indianapolis-based Eli Lilly and Co. has made to increase its cancer-treatment pipeline.
TechPoint announced 17 awards Friday night at its Mira Awards gala in Carmel. The annual awards program recognizes achievements in Indiana’s tech sector.
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal analysis and regulatory compliance.
The region stands out for its prowess in invention and innovation, but competing markets have mastered telling their stories, according to speakers at IBJ’s Life Sciences Power Breakfast.
Health insurers are raising questions about the Trump administration’s plan to cover obesity drugs in Medicare next year.
Lilly has been bringing in record revenue from its weight-loss medicines, but continues to diversify its pipeline candidates through acquisitions of biotech companies that are developing new genetic therapies for cancer and other disorders.
The new class of GLP-1 drugs are generally considered safe. Their metabolic effects have been scrutinized in studies, but their psychological impact is far less understood.
The Indianapolis-based pharmaceutical giant and the state’s Office of Energy Development signed a nonbinding letter of intent to explore the potential deployment of small modular reactors.
The Indianapolis-based drugmaker has started shipping the new pill to retail pharmacies.
Trump wrote that he deemed such actions necessary “to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.”
The daily oral medication, which will be branded as Foundayo, is expected to begin shipping Monday.
Centessa Pharmaceuticals is developing treatments to address daytime sleepiness and other neurological conditions.
